Skip to main content

Advertisement

SpringerLink
Log in

RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

As a result of alternative splicing and differential promoter usage, RASSF5 exists in at least three isoforms (RASSF5A–RASSF5C), which may play different roles in tumorigenesis. The present study was to detect the role of RASSF5A, B and C in esophageal squamous cell carcinoma (ESCC) and clarify the critical CpG sites of RASSF5A, in order to clarify more information on the role of RASSF5 with regard to the pathogenesis of ESCC. Frequent silencing of RASSF5A but not RASSF5B and RASSF5C were found in esophageal cancer cell lines and the silencing of RASSF5A may be reversed by 5-Aza-dC or TSA treatment. The aberrant CpG island 1 methylation of RASSF5A induces silencing of its expression in TE13 cell line. Decreased mRNA and protein expression of RASSF5A was observed in ESCC tumor tissues and was associated with RASSF5A CpG island 1 methylation status. Unlike RASSF5A, expression variation of RASSF5B and RASSF5C was not found in ESCC tissues. Aberrant promoter methylation of RASSF5C was also not found in ESCC. RASSF5A methylation and protein expression were independently associated with ESCC patients’ survival. These data indicated that the inactivation of RASSF5A through CpG island 1 methylation may play an important role in ESCC carcinogenesis, RASSF5A may be a functional tumor suppressor and may serve as a prognostic biomarker for ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Nagaraja V, Eslick GD (2014) Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol 5:67–76

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G (2010) Esophageal cancer: an update. Int J Surg 8:417–422

    Article  CAS  PubMed  Google Scholar 

  3. Sun G, Wang S, Hu X, Su J, Huang T, Yu J, Tang L, Gao W, Wang JS (2007) Fumonisin B1 contamination of home-grown corn in high-risk areas for esophageal and liver cancer in China. Food Addit Contam 24:181–185

    Article  CAS  PubMed  Google Scholar 

  4. Guohong Z, Min S, Duenmei W, Songnian H, Min L, Jinsong L, Hongbin L, Feng Z, Dongping T, Heling Y, Zhicai L, Shiyong L, Quansheng G, Xiaoyun L, Yuxia G (2010) Genetic heterogeneity of oesophageal cancer in high-incidence areas of southern and northern China. PLoS ONE 5:e9668

    Article  PubMed Central  PubMed  Google Scholar 

  5. Cully M, Downward J (2008) SnapShot: Ras Signaling. Cell 133 (1292–1292):e1

    PubMed  Google Scholar 

  6. Richter AM, Pfeifer GP, Dammann RH (2009) The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 1796:114–128

    CAS  PubMed  Google Scholar 

  7. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315–319

    Article  CAS  PubMed  Google Scholar 

  8. Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163–3172

    Article  CAS  PubMed  Google Scholar 

  9. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B (2009) Aberrant CpG Island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest 27:459–465

    Article  CAS  PubMed  Google Scholar 

  10. Guo W, Cui L, Wang C, Guo Y, Shen S, Kuang G, Dong Z (2014) Decreased expression of RASSF1A and up-regulation of RASSF1C is associated with esophageal squamous cell carcinoma. Clin Exp Metastasis 31:521–533

    Article  CAS  PubMed  Google Scholar 

  11. Vavvas D, Li X, Avruch J, Zhang XF (1998) Identification of Nore1 as a potential Ras effector. J Biol Chem 273:5439–5442

    Article  CAS  PubMed  Google Scholar 

  12. Tommasi S, Dammann R, Jin SG, Zhang XF, Avruch J, Pfeifer GP (2002) RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 21:2713–2720

    Article  CAS  PubMed  Google Scholar 

  13. Hesson L, Dallol A, Minna JD, Maher ER, Latif F (2003) NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22:947–954

    Article  CAS  PubMed  Google Scholar 

  14. Shinmura K, Tao H, Nagura K, Goto M, Matsuura S, Mochizuki T, Suzuki K, Tanahashi M, Niwa H, Ogawa H, Sugimura H (2011) Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma. Lung Cancer 71:19–27

    Article  PubMed  Google Scholar 

  15. Lee CK, Lee JH, Lee MG, Jeong SI, Ha TK, Kang MJ, Ryu BK, Hwangbo Y, Shim JJ, Jang JY, Lee KY, Kim HJ, Chi SG (2010) Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer 10:577

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, Leaner V, Clark GJ (2009) NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res 69:4629–4637

    Article  CAS  PubMed  Google Scholar 

  17. Geli J, Kogner P, Lanner F, Natalishvili N, Juhlin C, Kiss N, Clark GJ, Ekström TJ, Farnebo F, Larsson C (2008) Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma. Int J Cancer 123:389–394

    Article  CAS  PubMed  Google Scholar 

  18. Djos A, Martinsson T, Kogner P, Carén H (2012) The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Mol Cancer 11:40

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, Qian X, Sebo TJ, Erickson LA, Lloyd RV (2005) RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest 85:1065–1075

    Article  CAS  PubMed  Google Scholar 

  20. Irimia M, Fraga MF, Sanchez-Cespedes M, Esteller M (2004) CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 23:8695–8699

    Article  CAS  PubMed  Google Scholar 

  21. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH (2009) Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 22:1519–1526

    CAS  PubMed  Google Scholar 

  22. Geli J, Kiss N, Lanner F, Foukakis T, Natalishvili N, Larsson O, Kogner P, Höög A, Clark GJ, Ekström TJ, Bäckdahl M, Farnebo F, Larsson C (2007) The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. Endocr Relat Cancer 14:125–134

    Article  CAS  PubMed  Google Scholar 

  23. Lorente A, Mueller W, Urdangarín E, Lázcoz P, Lass U, von Deimling A, Castresana JS (2009) RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol 19:279–292

    Article  CAS  PubMed  Google Scholar 

  24. Macheiner D, Heller G, Kappel S, Bichler C, Stättner S, Ziegler B, Kandioler D, Wrba F, Schulte-Hermann R, Zöchbauer-Müller S, Grasl-Kraupp B (2006) NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol 45:81–89

    Article  CAS  PubMed  Google Scholar 

  25. Macheiner D, Gauglhofer C, Rodgarkia-Dara C, Grusch M, Brachner A, Bichler C, Kandioler D, Sutterlüty H, Mikulits W, Schulte-Hermann R, Grasl-Kraupp B (2009) NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer Res 69:235–242

    Article  CAS  PubMed  Google Scholar 

  26. Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23:206–215

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Meng CF, Zhu XJ, Peng G, Dai DQ (2007) Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines. World J Gastroenterol 13:6166–6171

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408

    Article  CAS  PubMed  Google Scholar 

  29. Das PM, Ramachandran K, vanWert J, Singal R (2004) Chromatin immunoprecipitation assay. Biotechniques 37:961–969

    CAS  PubMed  Google Scholar 

  30. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C (2005) Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 37:265–274

    Article  CAS  PubMed  Google Scholar 

  31. Sasaki M, Anast J, Bassett W, Kawakami T, Sakuragi N, Dahiya R (2003) Bisulfite conversion-specific and methylation-specific PCR: a sensitive technique for accurate evaluation of CpG methylation. Biochem Biophys Res Commun 309:305–309

    Article  CAS  PubMed  Google Scholar 

  32. Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y (2001) Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br J Cancer 85:1032–1036

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427–1431

    Article  CAS  PubMed  Google Scholar 

  34. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074–1080

    Article  CAS  PubMed  Google Scholar 

  35. Di Gioia S, Bianchi P, Destro A, Grizzi F, Malesci A, Laghi L, Levrero M, Morabito A, Roncalli M (2006) Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 6:89

    Article  PubMed Central  PubMed  Google Scholar 

  36. Hesson L, Bièche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, Latif F (2004) Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23:2408–2419

    Article  CAS  PubMed  Google Scholar 

  37. Chow LS, Lo KW, Kwong J, Wong AY, Huang DP (2004) Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 12:781–787

    CAS  PubMed  Google Scholar 

  38. Lázcoz P, Muñoz J, Nistal M, Pestaña A, Encío I, Castresana JS (2006) Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 6:254

    Article  PubMed Central  PubMed  Google Scholar 

  39. Chen SH, Chan SC, Chao YK, Yen TC (2013) Detection of synchronous cancers by fluorodeoxyglucose positron emission tomography/computed tomography during primary staging workup for esophageal squamous cell carcinoma in Taiwan. PLoS ONE 8:e82812

    Article  PubMed Central  PubMed  Google Scholar 

  40. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358:1118–1128

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by Grants from the National Natural Science Foundation (No. 81101854). We thank the patients and control individuals for taking part in this study.

Author information

Authors and Affiliations

  1. Laboratory of Pathology, Hebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Jiankang Road 12, Shijiazhuang, Hebei, China

    Wei Guo, Cong Wang, Yanli Guo, Supeng Shen, Xin Guo, Gang Kuang & Zhiming Dong

Authors
  1. Wei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanli Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Supeng Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gang Kuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhiming Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhiming Dong.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 22 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, W., Wang, C., Guo, Y. et al. RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma. Clin Exp Metastasis 32, 83–98 (2015). https://doi.org/10.1007/s10585-015-9693-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-015-9693-6

Keywords

Search

Navigation